
|Articles|November 1, 2004
Plans review pediatric antidepressant use in wake of FDA label change
By withholding information about some antidepressant medications that cause an increase in suicidal tendencies among teenagers, the Food and Drug Administration (FDA) created heightened public concern about the value of antidepressants.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
2
FDA Approves Gazyva for Lupus Nephritis in Adults
3
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
4
Making Sense of the Eye Pain-Headache Connection | AAO 2025
5